| 25.41 0.05 (0.2%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.53 | 1-year : | 36.83 |
| Resists | First : | 27 | Second : | 31.53 |
| Pivot price | 25.33  |
|||
| Supports | First : | 24.52 | Second : | 23 |
| MAs | MA(5) : | 25.66 |
MA(20) : | 25.43 |
| MA(100) : | 21.98 |
MA(250) : | 18.76 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 52.7 |
D(3) : | 58.3 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 27 | Low : | 13.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XOMA ] has closed below upper band by 47.0%. Bollinger Bands are 31.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.51 - 25.64 | 25.64 - 25.76 |
| Low: | 24.78 - 24.91 | 24.91 - 25.05 |
| Close: | 25.2 - 25.41 | 25.41 - 25.62 |
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Thu, 25 Apr 2024
XOMA secures $9M from FDA nod on Day One's OJEMDA drug - Investing.com Canada
Thu, 25 Apr 2024
Learn to Evaluate (XOMA) using the Charts - Stock Traders Daily
Thu, 25 Apr 2024
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM ... - The Bakersfield Californian
Thu, 25 Apr 2024
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for ... - GlobeNewswire
Thu, 25 Apr 2024
Xoma earns $9M milestone as FDA grants approval of Day One's NDA for OJEMDA - TipRanks.com - TipRanks
Mon, 22 Apr 2024
FDA Action Alert: ImmunityBio, Aquestive, XOMA and More - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 66.5 (%) |
| Shares Short | 274 (K) |
| Shares Short P.Month | 292 (K) |
| EPS | -4.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.71 |
| Profit Margin | 0 % |
| Operating Margin | -310 % |
| Return on Assets (ttm) | -7.4 % |
| Return on Equity (ttm) | -38.4 % |
| Qtrly Rev. Growth | 23.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.4 |
| EBITDA (p.s.) | -1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -6.29 |
| PEG Ratio | -0.7 |
| Price to Book value | 3.29 |
| Price to Sales | 62.08 |
| Price to Cash Flow | -16.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|